Abstract: Objective To study the therapeutic effect and safety of argatroban and heparin drugs for patients receiving anticoagulant therapy during hemodialysis. Methods Eighty patients receiving hemodialysis were randomly divided into argatroban group（n=30）,common heparin group（n=25）,and low molecular weight heparin group（n=25） according to different anticoagulant drugs used for them.Their activated partial thromboplastin time（APTT）,PLT,and H-PF4 antibody were detected before and after hemodialysis.Coagulation in haemodialysers was scored and bleeding in the patients was observed. Results No difference was observed in coagulation in the haemodialysers between argatroban group and common heparin group,and in APTT,PLT,and H-PF4 antibody between argatroban group and low molecular weight heparin group.However,the APTT,PLT,and H-PF4 antibody were significantly better in argatroban group than in common heparin group.The incidence of hemorrhage was 0%,24%,and 12%,respectively,in argatroban group,common heparin group,and low molecular weight heparin group. Conclusion Argatroban infusion from the artery is as effective as heparin drugs for patients receiving anticoagulant therapy during hemodialysis with less negative influence on their coagulation,hemorrhage and no risk of heparin-induced thrombocytopenia（HIT）.